



94TH GENERAL ASSEMBLY

State of Illinois

2005 and 2006

HB4779

Introduced 1/18/2006, by Rep. Elizabeth Coulson - Patricia R. Bellock

SYNOPSIS AS INTRODUCED:

305 ILCS 5/5-5.12

from Ch. 23, par. 5-5.12

Amends the Illinois Public Aid Code. In provisions concerning the Medicaid program, provides that the Department of Healthcare and Family Services may not impose requirements for prior approval based on a preferred drug list for anti-retroviral, anti-hemophilic factor concentrates, or any atypical antipsychotics, conventional antipsychotics, or anticonvulsants used for the treatment of serious mental illnesses (instead of providing that the Department may not impose such requirements until 30 days after it has conducted a study of the impact of such requirements on patient care and submitted a report to the Speaker of the House of Representatives and the President of the Senate). Effective immediately.

LRB094 15365 DRJ 50556 b

FISCAL NOTE ACT
MAY APPLY

1 AN ACT concerning public aid.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Public Aid Code is amended by
5 changing Section 5-5.12 as follows:

6 (305 ILCS 5/5-5.12) (from Ch. 23, par. 5-5.12)

7 Sec. 5-5.12. Pharmacy payments.

8 (a) Every request submitted by a pharmacy for reimbursement
9 under this Article for prescription drugs provided to a
10 recipient of aid under this Article shall include the name of
11 the prescriber or an acceptable identification number as
12 established by the Department.

13 (b) Pharmacies providing prescription drugs under this
14 Article shall be reimbursed at a rate which shall include a
15 professional dispensing fee as determined by the Illinois
16 Department, plus the current acquisition cost of the
17 prescription drug dispensed. The Illinois Department shall
18 update its information on the acquisition costs of all
19 prescription drugs no less frequently than every 30 days.
20 However, the Illinois Department may set the rate of
21 reimbursement for the acquisition cost, by rule, at a
22 percentage of the current average wholesale acquisition cost.

23 (c) (Blank).

24 (d) The Department shall not impose requirements for prior
25 approval based on a preferred drug list for anti-retroviral,
26 anti-hemophilic factor concentrates, or any atypical
27 antipsychotics, conventional antipsychotics, or
28 anticonvulsants used for the treatment of serious mental
29 illnesses ~~until 30 days after it has conducted a study of the~~
30 ~~impact of such requirements on patient care and submitted a~~
31 ~~report to the Speaker of the House of Representatives and the~~
32 ~~President of the Senate.~~

1 (Source: P.A. 93-106, eff. 7-8-03; 94-48, eff. 7-1-05.)

2 Section 99. Effective date. This Act takes effect upon
3 becoming law.